These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34089797)

  • 1. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial.
    Hamzavi I; Rosmarin D; Harris JE; Pandya AG; Lebwohl M; Gottlieb AB; Butler K; Kuo FI; Sun K; Grimes P
    J Am Acad Dermatol; 2022 Jun; 86(6):1398-1401. PubMed ID: 34089797
    [No Abstract]   [Full Text] [Related]  

  • 2. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
    N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials.
    Ehsan M; Rehman AU; Ayyan M; Cheema HA; Ahmad TZ; Mustafa B; Shahid A; Khedro T; Ismail H; Nashwan AJ
    J Cosmet Dermatol; 2024 Jan; 23(1):350-353. PubMed ID: 38161317
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruxolitinib cream (Opzelura) for nonsegmental vitiligo.
    Med Lett Drugs Ther; 2022 Oct; 64(1660):158-159. PubMed ID: 36206166
    [No Abstract]   [Full Text] [Related]  

  • 9. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
    Grossmann MC; Haidari W; Feldman SR
    J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: A single center retrospective study.
    Stefanko NS; Quan VL; Chovatiya R
    J Am Acad Dermatol; 2023 Aug; 89(2):415-417. PubMed ID: 37094652
    [No Abstract]   [Full Text] [Related]  

  • 11. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Janssen JC; Mulder EEAP; van der Veldt AAM
    N Engl J Med; 2023 Jan; 388(3):283. PubMed ID: 36652364
    [No Abstract]   [Full Text] [Related]  

  • 12. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. Reply.
    Rosmarin D; Kornacki D; Ezzedine K
    N Engl J Med; 2023 Jan; 388(3):284. PubMed ID: 36652365
    [No Abstract]   [Full Text] [Related]  

  • 13. Eyelid Vitiligo Treatment with Topical Ruxolitinib.
    Camacho MB; Han MM; Wang JN; Dermarkarian CR; Tao JP
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e70. PubMed ID: 37450618
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
    Hwang JR; Driscoll MS
    Ann Pharmacother; 2023 Aug; 57(8):948-955. PubMed ID: 36564903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical ruxolitinib: A new treatment for vitiligo.
    Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
    Rothstein B; Joshipura D; Saraiya A; Abdat R; Ashkar H; Turkowski Y; Sheth V; Huang V; Au SC; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    J Am Acad Dermatol; 2017 Jun; 76(6):1054-1060.e1. PubMed ID: 28390737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies.
    Blauvelt A; Szepietowski JC; Papp K; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Kircik L
    J Am Acad Dermatol; 2023 Mar; 88(3):651-653. PubMed ID: 36113614
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.
    Asawanonda P; Klahan SO
    Photomed Laser Surg; 2010 Oct; 28(5):679-84. PubMed ID: 20961233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.